The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
- Published In:
- Metabolism: clinical and experimental, 48(7), 935-41 (1999)
- Authors:
- Nyholm, B, Orskov, L, Hove, K Y, Gravholt, C H, Møller, N, Alberti, K G, Moyses, C, Kolterman, O, Schmitz, O
- Database ID:
- RPEP-00547
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-00547APA
Nyholm, B; Orskov, L; Hove, K Y; Gravholt, C H; Møller, N; Alberti, K G; Moyses, C; Kolterman, O; Schmitz, O. (1999). The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.. Metabolism: clinical and experimental, 48(7), 935-41.
MLA
Nyholm, B, et al. "The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.." Metabolism: clinical and experimental, 1999.
RethinkPeptides
RethinkPeptides Research Database. "The amylin analog pramlintide improves glycemic control and ..." RPEP-00547. Retrieved from https://rethinkpeptides.com/research/nyholm-1999-the-amylin-analog-pramlintide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.